TV News LIES

Thursday, Jun 30th

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Scientists: Marijuana Can Help Deteriorate Alzheimer’s

Pot helps deteriorate AlzheimersSalk Institute scientists have found preliminary evidence that tetrahydrocannabinol (THC) and other compounds found in marijuana...

Supreme Court rejects pharmacists' religious rights appeal

Plan B contraceptiveThe U.S. Supreme Court on Tuesday declined to hear an appeal from Washington state pharmacists who...

Tennessee hospital leads U.S. in doctors taking drug industry money

St. Francis-Bartlett Hospital, TennesseeA small for-profit hospital on the outskirts of Memphis has the highest rate of doctors who...

Millions exposed to dangerous lead levels in US drinking water, report finds

Millilons exposed to dangersMore than 18 million Americans are served drinking water by providers that have violated federal laws...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!